Molecular diagnosis of gastrointestinal cancers: The application to clinical practice

International Journal of Clinical Oncology

Volumn 1, Issue 2, 1996, Pages 63-68

  Tahara, Eiichi ^a   Yasui, Wataru ^a   Yokozaki, Hiroshi ^a   Shimamoto, Fumio ^b  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CD 44; Gastrointestinal cancer; Genetic instability; Molecular diagnosis

Indexed keywords

EID: 0001356195     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02348269     Document Type: Review

References (54)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
2. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993;119:265-272.
3. Service RF. Stalking the start of colon cancer. Science 1994;263:1559-1560.
4. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-1065.
5. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995;1:309-320.
6. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-237.
7. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038.
8. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients. Nat Med 1996;2:169-174.
9. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW. Telomerase. Cold Spring Harb Symp Quant Biol 1994;59:307-315.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
11. Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T, Tahara E. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1995;1:1245-1251.
12. Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 1995;75(suppl):1410-1417.
13. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-2983.
14. Yoshida K, Kawami H, Kuniyasu H, Nishiyama M, Yasui W, Hirai T, Toge T, Tahara E. Coamplification of cyclin D, hst-1 and int-2 genes is a good biological marker of high malignancy for human esophageal carcinomas. Oncol Rep 1994;1:493-496.
15. MTS1 gene status in human esophageal carcinoma cell lines. J Exp Ther Oncol 1996;1:7-12.
16. Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, Tahara E. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995;86:617-621.
17. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, Hisatsugu T, Tahara E. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-28.
18. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol 1996;1:88-94.
19. Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with Ki-67 antigen expression and abnormal accumulation of p53. Virchows Archiv 1996;(in press).
20. Keynomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer. Proc Natl Acad Sci USA 1993;90:1112-1116.
21. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-385.
22. Noda A, Ning Y, Venable SF, Percira-Smith OM, Smith JR. Cloning of senescent cell derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;11:90-98.
23. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 1993;75:805-816.
24. Toyoshima H, Hunter T. p27, novel inhibitor of G1 cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
25. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994;91:5291-5295.
26. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
27. Hammon GJ, Beach D. p151NK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 1994;371:257-261.
28. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5'CpG island methylation is associated with transcription silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-692.
29. sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 1995;10:835-840.
30. cipl in muscle and other terminally differentiating cells. Science 1995;267:1024-1027.
31. Akagi M, Yasui W, Akama Y, Yokozaki H, Tahara H, Haruma K, Kajiyama G, Tahara E. Inhibition of cell growth by transforming growth factor β1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Jpn J Cancer Res 1996;87:377-384.
32. WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relation with p53 status and proliferative activity. J Pathol 1996;(in press).
33. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature 1995;9:48-55.
34. Semba S, Yokozaki H, Yamamoto S, Yasui W, Tahara E. Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 1996;77S:1620-1627.
35. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kanzler KW, Lutterbaugh J, Park K, Bang YJ, Lee HY, Park JG, Lynch HT, Roberts AB, Vogelstein B, Markowitz SD. A transforming growth factor B receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547.
36. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
37. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994;54:4750-4755.
38. Horii A, Han HJ, Shimada M, Yanagisawa A, Kato Y, Ohta H, Yasui W, Tahara E, Nakamura Y. Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. Cancer Res 1994;54:3373-3375.
39. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-1929.
40. Rhyu MS. Telomeres, telomerase and immortality. J Natl Cancer Inst 1995;87:884-894.
41. Tahara E, Kuniyasu H, Yasui W, Yokozaki H. Gene alterations in intestinal metaplasia and gastric cancer. Eur J Gastroenterol Hepatol 1994;6(suppl 1):S97-S101.
42. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990;346:866-868.
43. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995;55:2533-2536.
44. Blasco MA, Rizen M, Greider CW, Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 1996;12:200-204.
45. Cooper DL, Dougherty GJ.To metastasize or not? Selection of CD44 splice sites. Nat Med 1995;1:635-637.
46. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-1058.
47. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
48. Dougherty GJ, Dougherty ST, Eaves CJ, McBride WH. Expression of human CD44 R1 enhances the metastatic capacity of murine fibrosarcoma cells. Proc Annu Meet Am Asso Cancer Res 1992;33:A206.
49. Yoshida K, Bolodeoku J, Sugino T, Goodison S, Matsumura Y, Warren BF, Toge T, Tahara E and Tarin D. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res 1995;55:4273-1277.
50. Higashikawa K, Yokozaki H, Ue T, Taniyama K, Ishikawa T, Tarin D, Tahara E. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 1996;66:11-17.
51. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC, Tarin D. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncologial opportunities. J Pathol 1995;177:11-20.
52. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G, Aruffo A. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995;128:687-698.
53. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Efa-1), Science 1996;271:509-512.
54. Tarin D. A new strategy of molecular diagnosis of gastrointestinal cancer. Jpn J Cancer Res 1995;86:cover article.